文献速递免疫规划妇幼与学校卫生

9价人乳头瘤病毒疫苗在中国9-45岁女性中的免疫原性和安全性:一项3期开放标签研究

Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
PubMed 文献 · Vaccine · 2022-04-26

这项3期开放标签研究比较了9价HPV疫苗在中国9-19岁和27-45岁女性与20-26岁女性中的免疫原性和安全性,共纳入1990人。结果显示9-19岁组抗体GMT和27-45岁组血清阳转率均非劣于20-26岁组,疫苗总体耐受良好,未发生疫苗相关严重不良事件。

要点

  • 9-19岁女性接种3剂后抗HPV6/11/16/18/31/33/45/52/58抗体GMT非劣于20-26岁女性。
  • 27-45岁女性血清阳转率非劣于20-26岁女性,各型别阳转率均>99%。
  • 未报告疫苗相关严重不良事件、因不良事件退出和死亡。

核心结论

  • 中国9-19岁和27-45岁女性接种9价HPV疫苗诱导的抗体应答非劣于20-26岁女性,疫苗总体耐受良好。

研究设计与样本

  • 3期开放标签研究(NCT03903562),纳入1990名9-45岁中国女性,其中9-19岁690人、20-26岁650人、27-45岁650人,均接种3剂9价HPV疫苗。
  • 研究将持续至第3剂后54个月,以评估9-19岁中国女孩的抗体持久性。

主要发现

  • 第3剂后1个月,符合方案免疫原性人群中>99%的参与者对每种疫苗HPV型别发生血清阳转。
  • 9-19岁组抗HPV6/11/16/18/31/33/45/52/58抗体GMT非劣于20-26岁组。
  • 27-45岁组抗HPV6/11/16/18/31/33/45/52/58血清阳转百分比非劣于20-26岁组。
  • 注射部位和全身不良事件发生率:9-19岁组分别为43.3%和50.9%,20-26岁组分别为50.5%和57.1%,27-45岁组分别为43.8%和43.4%。
  • 未报告疫苗相关严重不良事件、因不良事件退出和死亡。

关键数值与推荐

  • 免疫原性非劣效性评价指标为第3剂后1个月抗HPV6/11/16/18/31/33/45/52/58抗体GMT和血清阳转百分比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3, open-label study (NCT03903562) compared 9vHPV vaccine immunogenicity and safety in Chinese females aged 9-19 years and 27-45 years with Chinese females aged 20-26 years; we report results from day 1 through 1 month post-Dose 3. The study will continue through 54 months post-Dose 3 to assess antibody persistence in Chinese girls aged 9-19 years. METHODS: Participants aged 9-45 years received three doses of the 9vHPV vaccine. Geometric mean titers (GMTs) and seroconversion percentages for anti-HPV6/11/16/18/31/33/45/52/58 antibodies were determined by competitive Luminex immunoassay in serum samples obtained at day 1 and 1 month post-Dose 3. Adverse events (AEs) within 30 days post-vaccination and serious AEs (SAEs) occurring at any time were recorded. RESULTS: In total, 1990 participants (690 aged 9-19 years; 650 aged 20-26 years; 650 aged 27-45 years) were enrolled. At 1 month post-Dose 3, >99% of participants in the per-protocol immunogenicity population seroconverted to each vaccine HPV type. Anti-HPV6/11/16/18/31/33/45/52/58 antibody GMTs in the 9-19-year age group were non-inferior to those in participants aged 20-26 years. Anti-HPV6/11/16/18/31/33/45/52/58 seroconversion percentages in the 27-45-year age group were non-inferior to those in participants aged 20-26 years. Injection-site and systemic AEs were reported by 43.3% and 50.9%, 50.5% and 57.1%, and 43.8% and 43.4% of participants aged 9-19, 20-26, and 27-45 years, respectively. There were no vaccine-related SAEs, discontinuations due to AEs, and deaths. CONCLUSION: Antibody responses induced by 9vHPV vaccination in Chinese females aged 9-19 years and 27-45 years were non-inferior to those in Chinese females aged 20-26 years. The vaccine was generally well tolerated. CLINICALTRIALS: gov Identifier: NCT03903562.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lv H, Wang S, Liang Z, et al. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study. Vaccine. 2022. PMID: 35487814. doi:10.1016/j.vaccine.2022.02.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。